BALTIMORE, Dec. 10, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based, clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform, announced today that it has been featured in Biospace’s article “Setting the Stage for ASH 2022.”
The link to the article: Biospace – Setting the Stage for ASH 2022
About Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform. The company has two products in Phase I/II clinical trials (ClinicalTrials.gov Identifiers: NCT04211714 and NCT04863131) using its proprietary c-srRNA platform. For more information visit ElixirgenTherapeutics.com.
This press release may contain “forward-looking” statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in pharmaceutical research and development. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statements in the future, even if new information becomes available.
Media Relations Elixirgen Therapeutics, Inc. Phone: (443) 451-5300 Media@ElixirgenTherapeutics.com